Your session is about to expire
← Back to Search
Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome (ECP Trial)
ECP Trial Summary
This trial is studying how well Extracorporeal Photopheresis works in treating patients with either refractory or newly diagnosed Bronchiolitis Obliterans Syndrome after lung transplantation.
ECP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowECP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ECP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a condition that may make it hard for you to do breathing tests.I have been diagnosed with BOS, showing a significant decline in lung function.I have not had ECP therapy in the last 6 months.My BOS developed either before 2016 or after 2022.I have a history of disorders related to lymphocyte proliferation.I have not had any cancer, except for skin cancer, in the last 5 years.I have skin or eye conditions that worsen with light-sensitive treatments.Regular monitoring of lung function is needed before diagnosing a new lung condition called BOS.My lung function decline is not due to bronchiolitis obliterans syndrome.I have received a lung transplant.Your lung function has declined too quickly in the last 6 or 9 months.I am part of a trial for a new treatment for BOS.I am 18 years old or older.I have been diagnosed with BOS, with two tests showing my lung function has dropped by 20% or more.My lung function is decreasing despite treatment.I've had a physical exam and blood tests within the last two weeks.My lung function has significantly worsened since being diagnosed with BOS.You need to have at least five recorded breathing test measurements taken at different times over the 9 months before joining the study.You have had regular breathing tests in the past.I have had cancer before.I do not have the natural lens in my eye.I have been treated for sudden worsening of my lung function due to rejection.You have recently had low white blood cell count.Patients must have specific measurements of lung function before and after a lung transplant.My lung function decline is due to restrictive lung issues not related to BOS.I have received ECP Therapy for BOS.I've had a physical exam and blood test within the last two weeks.
- Group 1: Newly Diagnosed Bronchiolitis Obliterans (NEW BOS)
- Group 2: Refractory Bronchiolitis Obliterans Syndrome (REFRACTORY BOS)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it permissible to use this medication according to the FDA?
"The safety of this Phase 3 trial's intervention ranks a 3 on our team's scale at Power. This is due to there being both efficacy data as well as multiple rounds of safety data."
Are we currently able to sign participants up for this research study?
"Unfortunately, this particular clinical trial is not looking for new candidates at the moment. The information on clinicaltrials.gov suggests that the trial was originally posted on 1/1/2015 and was last updated on 6/20/2022. However, there are many other trials (1465 to be exact) that are actively recruiting patients."
Share this study with friends
Copy Link
Messenger